Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adult patients with chronic kidney disease stages 1–3 at initiat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nephrol Dial Transplant
Autors principals: Gansevoort, Ron T., Arici, Mustafa, Benzing, Thomas, Birn, Henrik, Capasso, Giovambattista, Covic, Adrian, Devuyst, Olivier, Drechsler, Christiane, Eckardt, Kai-Uwe, Emma, Francesco, Knebelmann, Bertrand, Le Meur, Yannick, Massy, Ziad A., Ong, Albert C.M., Ortiz, Alberto, Schaefer, Franz, Torra, Roser, Vanholder, Raymond, Więcek, Andrzej, Zoccali, Carmine, Van Biesen, Wim
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2016
Matèries:
Cutting-Edge Renal Science
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4762400/
https://ncbi.nlm.nih.gov/pubmed/26908832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfv456
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars